Beigel JH, Aga E, Elie-Turenne MC, et al. - Whether high-titre anti-influenza immune plasma (haemagglutination inhibition antibody titre ≥ 1:80) is clinically effective than standard low-titre plasma (≤ 1:10) for improving outcomes in patients with severe influenza A infection was prospectively assessed in this randomised, double-blind, phase 3 trial conducted at 41 US medical centres. The eligibility criteria included the presence of PCR-confirmed influenza A infection in children and adults, with a National Early Warning score of 3 or greater, and the start of illness within 6 days prior to randomisation. Using randomization (2:1), researchers allocated the patients to receive either two units (or paediatric equivalent) of high-titre plasma (high-titre group) or low-titre plasma (low-titre group). The participants were observed for 28 days from randomisation. Findings revealed no significant benefit of high-titre anti-influenza plasma over non-immune plasma. Treating patients with severe influenza A with immune plasma was not supported owing to the insufficiency of the benefit observed in this study.